A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
Conditions
Bladder Cancer · Squamous Cell Carcinoma of the Lung · Esophageal Squamous Cell Carcinoma · Tongue Squamous Cell Carcinoma · Cutaneous Squamous Cell Cancer · Penile Squamous Cell Carcinoma · Anal Squamous Cell Carcinoma · Vulvar Squamous Cell Carcinoma · Cervical Squamous Cell Carcinoma · Vaginal Squamous Cell Carcinoma · Urethral Squamous Cell Carcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
City of Hope, Duarte, California, United States
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Yale University Cancer Center, New Haven, Connecticut, United States
The Winship Cancer Institute Emory University, Atlanta, Georgia, United States
START Midwest, Grand Rapids, Michigan, United States
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Columbia University Irving Medical Center, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States
SCRI, Nashville, Tennessee, United States
MD Anderson Cancer Center, Houston, Texas, United States
Virginia Cancer Specialists, Fairfax, Virginia, United States
Study leads
EvolveImmune Study Team
Study Director
EvolveImmune United, Inc